NEWS
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
Petros Pharmaceuticals (NASDAQ:PTPI) has announced successful results from an initial study testing consumer comprehension of its App Technology messaging for STENDRA (avanafil). The study, part of the FDA pathway for over-the-counter (OTC) access, showed high comprehension rates:
- 29 out of 31 objectives scored >90% comprehension Point Estimate (PE)
- 30 scored >86.7% PE
- All scored >80% PE
- 21 scored 100% PE
The company is now conducting a larger scale study with about 400 patients, expected to conclude in Q4 2024. This progress marks a significant step towards expanding consumer access to STENDRA through OTC distribution.
- 29 out of 31 objectives scored >90% comprehension Point Estimate (PE)
- 30 scored >86.7% PE
- All scored >80% PE
- 21 scored 100% PE
The company is now conducting a larger scale study with about 400 patients, expected to conclude in Q4 2024. This progress marks a significant step towards expanding consumer access to STENDRA through OTC distribution.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment